Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer

Clin Obstet Gynecol. 2012 Mar;55(1):131-55. doi: 10.1097/GRF.0b013e318248050d.

Abstract

This chapter reviews some of the sentinel Gynecologic Oncology Group (GOG) ovarian trials, describes their rationale, provides summary tables for reference, and is organized into early ovarian cancer (GOG 1, 7601, 7602, 95, 157, 175, 212), advanced ovarian cancer optimal (2, 25, 52, 104, 114, 158, 172, 182, 178, 212, 252), and suboptimal disease (3, 22, 47, 97, 111, 162, 182, 218, 252, 262).

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / therapeutic use
  • Clinical Trials as Topic
  • Female
  • Humans
  • Laparotomy
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial / pathology
  • Neoplasms, Glandular and Epithelial / therapy*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*
  • Paclitaxel / analogs & derivatives
  • Paclitaxel / therapeutic use
  • Polyglutamic Acid / analogs & derivatives
  • Polyglutamic Acid / therapeutic use
  • Second-Look Surgery

Substances

  • Polyglutamic Acid
  • Carboplatin
  • Paclitaxel
  • paclitaxel poliglumex